Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.56 |
| ▸ | IGF1R | P08069 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | SLC40A1 | Q9NP59 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2175901 | 0.91 | SCN2A (0.47) | TRPV1IGF1RHIF1AKMT2AMEN1 | |
| SCHEMBL5668846 | 0.87 | IGF1R (0.47) | IGF1RHIF1AKMT2AMEN1SLC40A1 | |
| SCHEMBL4390454 | 0.87 | MAPT (0.46) | TRPV1HIF1AKMT2AMEN1SLC40A1 | |
| SCHEMBL4387635 | 0.87 | SGMS1 (0.47) | TRPV1KMT2AMEN1KDM4ECYP1A2 | |
| SCHEMBL5667982 | 0.86 | KDM4E (0.47) | KMT2AMEN1SLC40A1KDM4ENPC1 | |
| SCHEMBL12407087 | 0.86 | HPGD (0.47) | KMT2AMEN1SLC40A1KDM4ENPC1 | |
| SCHEMBL2173603 | 0.85 | SGMS1 (0.49) | TRPV1IGF1RHIF1ASLC40A1 | |
| SCHEMBL2172869 | 0.85 | CYP1A2 (0.43) | TRPV1HIF1AKMT2AMEN1KDM4E | |
| SCHEMBL4389894 | 0.85 | TRPV1 (0.58) | TRPV1KMT2AMEN1CYP1A2CYP3A4 | |
| SCHEMBL4396904 | 0.84 | MAPT (0.48) | TRPV1KMT2AMEN1KDM4ECYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7973061-B2 | Anaplastic lymphoma kinase modulators and methods of use | EXELIXIS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-7973061-B2 | Anaplastic lymphoma kinase modulators and methods of use | EXELIXIS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-7973061-B2 | Anaplastic lymphoma kinase modulators and methods of use | EXELIXIS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-20090186905-A1 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| US-20090186905-A1 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186905-A1 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | ALK, BCL3, MCL1 | TRPV1 3477/4885IGF1R 367/4885HIF1A 1345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.